by Harry Paul Erba, MD, PhD; Guillermo Garcia-Manero, MD; and David Sallman, MD
The development of novel therapies and combination regimens for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have ......READ MORE
by Harry Paul Erba, MD, PhD; Guillermo Garcia-Manero, MD; and David Sallman, MD
Treatment decisions for patients with high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) are guided by the individual pat......READ MORE
Conversations with patients about initial therapy for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML) may include the ......READ MORE
Although patients with acute myeloid leukemia (AML) may experience neutropenia, anemia, or thrombocytopenia, supportive care measures are available......READ MORE
Hypomethylating agents are the foundation of treatment for patients with myelodysplastic syndrome (MDS), but many individuals do not achieve durabl......READ MORE
Preliminary results from clinical trials with novel immune checkpoint inhibitors (ICIs), including magrolimab and sabatolimab, demonstrated that th......READ MORE
